XYLOCAINE

Xylocaine Adverse Events Reported to the FDA Over Time

How are Xylocaine adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Xylocaine, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Xylocaine is flagged as the suspect drug causing the adverse event.

Most Common Xylocaine Adverse Events Reported to the FDA

What are the most common Xylocaine adverse events reported to the FDA?

Convulsion	288 (1.63%)
Cardiac Arrest	208 (1.18%)
Dizziness	197 (1.12%)
Loss Of Consciousness	190 (1.08%)
Drug Toxicity	183 (1.04%)
Anaphylactic Shock	182 (1.03%)
Drug Ineffective	167 (.95%)
Dyspnoea	165 (.93%)
Hypotension	162 (.92%)
Overdose	159 (.9%)
Anaesthetic Complication	150 (.85%)
	Show More
Blood Pressure Decreased	147 (.83%)
Tachycardia	142 (.8%)
Nausea	135 (.76%)
Blood Pressure Increased	134 (.76%)
Drug Interaction	133 (.75%)
Pain	127 (.72%)
Shock	120 (.68%)
Bradycardia	119 (.67%)
Medication Error	114 (.65%)
Hypoaesthesia	111 (.63%)
Headache	105 (.59%)
Anaphylactic Reaction	99 (.56%)
Respiratory Arrest	91 (.52%)
Incorrect Route Of Drug Administrat...	90 (.51%)
Drug Hypersensitivity	88 (.5%)
Methaemoglobinaemia	88 (.5%)
Erythema	87 (.49%)
Grand Mal Convulsion	86 (.49%)
Confusional State	84 (.48%)
Hypertension	84 (.48%)
Post Procedural Complication	82 (.46%)
Vomiting	82 (.46%)
Septic Arthritis Staphylococcal	80 (.45%)
Cyanosis	79 (.45%)
Ventricular Tachycardia	79 (.45%)
Agitation	78 (.44%)
Malaise	78 (.44%)
Oxygen Saturation Decreased	78 (.44%)
Heart Rate Increased	77 (.44%)
Pyrexia	77 (.44%)
Depressed Level Of Consciousness	74 (.42%)
Syncope	74 (.42%)
Bronchospasm	73 (.41%)
Coma	73 (.41%)
Somnolence	73 (.41%)
Tremor	73 (.41%)
Ventricular Fibrillation	72 (.41%)
Angioedema	71 (.4%)
Off Label Use	71 (.4%)
Hypersensitivity	70 (.4%)
Palpitations	70 (.4%)
Urticaria	70 (.4%)
Anxiety	67 (.38%)
Cardio-respiratory Arrest	67 (.38%)
Hyperhidrosis	66 (.37%)
Drug Exposure During Pregnancy	65 (.37%)
Procedural Complication	65 (.37%)
Wrong Technique In Drug Usage Proce...	65 (.37%)
Pallor	64 (.36%)
Toxic Anterior Segment Syndrome	64 (.36%)
Oedema Peripheral	63 (.36%)
Asthenia	62 (.35%)
Musculoskeletal Pain	62 (.35%)
Heart Rate Decreased	58 (.33%)
Pain In Extremity	56 (.32%)
Paraesthesia	56 (.32%)
Visual Acuity Reduced	56 (.32%)
Fatigue	54 (.31%)
Injection Site Pain	52 (.29%)
Weight Decreased	52 (.29%)
Feeling Abnormal	50 (.28%)
Hypertensive Crisis	50 (.28%)
Rash	50 (.28%)
Burning Sensation	49 (.28%)
Death	49 (.28%)
Insomnia	49 (.28%)
Gait Disturbance	48 (.27%)
Pruritus	48 (.27%)
Circulatory Collapse	47 (.27%)
Muscular Weakness	47 (.27%)
Pulmonary Oedema	47 (.27%)
Restlessness	47 (.27%)
Unresponsive To Stimuli	47 (.27%)
Diplopia	45 (.25%)
Pulse Absent	45 (.25%)
Sinus Tachycardia	45 (.25%)
Ventricular Extrasystoles	45 (.25%)
Apnoea	44 (.25%)
Chondrolysis	44 (.25%)
Condition Aggravated	44 (.25%)
Fall	43 (.24%)
Mydriasis	43 (.24%)
Product Quality Issue	43 (.24%)
Accidental Overdose	42 (.24%)
Arthralgia	42 (.24%)
Hypoxia	42 (.24%)
Speech Disorder	42 (.24%)
Atrial Fibrillation	41 (.23%)
Dysarthria	40 (.23%)
Back Pain	39 (.22%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Xylocaine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Xylocaine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Xylocaine

What are the most common Xylocaine adverse events reported to the FDA?

Neurological	1434 (8.12%)
Cardiac Arrhythmias	1098 (6.22%)
Cardiac And Vascular Investigations	681 (3.86%)
Medication Errors	677 (3.84%)
Respiratory	655 (3.71%)
Procedural And Device Related Injur...	571 (3.23%)
Epidermal And Dermal Conditions	558 (3.16%)
Allergic Conditions	480 (2.72%)
Seizures	438 (2.48%)
Therapeutic And Nontherapeutic Effe...	406 (2.3%)
Infections - Pathogen Unspecified	389 (2.2%)
	Show More
Decreased And Nonspecific Blood Pre...	344 (1.95%)
Gastrointestinal Signs	336 (1.9%)
Chemical Injury And Poisoning	288 (1.63%)
Movement Disorders	282 (1.6%)
Injuries	278 (1.57%)
Musculoskeletal And Connective Tiss...	260 (1.47%)
Bacterial Infectious	235 (1.33%)
Vision	226 (1.28%)
Muscle	224 (1.27%)
Anxiety Disorders	213 (1.21%)
Administration Site Reactions	194 (1.1%)
Cardiac Disorder Signs	173 (.98%)
Ocular Infections, Irritations And ...	161 (.91%)
Bronchial Disorders	158 (.9%)
Joint	158 (.9%)
Metabolic, Nutritional And Blood Ga...	157 (.89%)
Coronary Artery	152 (.86%)
Ocular Neuromuscular	151 (.86%)
Angiedema And Urticaria	146 (.83%)
Hematology Investigations	135 (.76%)
Vascular Hypertensive	135 (.76%)
Skin Appendage Conditions	133 (.75%)
Deliria	124 (.7%)
Upper Respiratory Tract Disorders	121 (.69%)
Physical Examination Topics	111 (.63%)
Headaches	110 (.62%)
Vascular	110 (.62%)
Lower Respiratory Tract Disorders	107 (.61%)
Eye	105 (.59%)
Therapeutic Procedures And Supporti...	101 (.57%)
Body Temperature Conditions	100 (.57%)
Oral Soft Tissue Conditions	97 (.55%)
Hematological	93 (.53%)
Heart Failures	88 (.5%)
Fatal Outcomes	87 (.49%)
Psychiatric	87 (.49%)
Product Quality Issues	81 (.46%)
Sleep Disorders	79 (.45%)
Ocular Structural Change, Deposit A...	69 (.39%)
Renal Disorders	68 (.39%)
Hepatobiliary	67 (.38%)
Urinary Tract Signs	65 (.37%)
Neuromuscular	64 (.36%)
Gastrointestinal Motility And Defec...	61 (.35%)
Mental Impairment	59 (.33%)
Bone And Joint Injuries	58 (.33%)
Myocardial	58 (.33%)
Tongue Conditions	57 (.32%)
Tendon, Ligament And Cartilage	56 (.32%)
Neurological, Special Senses And Ps...	55 (.31%)
Lifestyle Issues	54 (.31%)
Bone Disorders	53 (.3%)
Changes In Physical Activity	52 (.29%)
Hepatic And Hepatobiliary	52 (.29%)
Disturbances In Thinking	49 (.28%)
Peripheral Neuropathies	49 (.28%)
Retina, Choroid And Vitreous Hemorr...	49 (.28%)
Spinal Cord And Nerve Root	49 (.28%)
Cranial Nerve Disorders	48 (.27%)
Head And Neck Therapeutic Procedure...	48 (.27%)
Electrolyte And Fluid Balance Condi...	45 (.25%)
Vascular Hemorrhagic	45 (.25%)
Obstetric And Gynecological Therape...	44 (.25%)
Anterior Eye Structural Change, Dep...	42 (.24%)
Arteriosclerosis, Stenosis, Vascula...	41 (.23%)
Toxicology And Therapeutic Drug Mon...	39 (.22%)
Mood Disorders	38 (.22%)
Water, Electrolyte And Mineral	38 (.22%)
Acid-base	36 (.2%)
Central Nervous System Vascular	36 (.2%)
Dental And Gingival Conditions	36 (.2%)
Depressed Mood Disorders	36 (.2%)
Enzyme	34 (.19%)
Immunology And Allergy	34 (.19%)
Suicidal And Self-injurious Behavio...	34 (.19%)
Hearing	33 (.19%)
Appetite And General Nutritional	32 (.18%)
Encephalopathies	32 (.18%)
Glucose Metabolism Disorders	32 (.18%)
Tissue	32 (.18%)
White Blood Cell	31 (.18%)
Bone And Joint Therapeutic Procedur...	30 (.17%)
Inner Ear And Viiith Cranial Nerve	27 (.15%)
Skin Vascular Abnormalities	26 (.15%)
Viral Infectious	26 (.15%)
Hepatobiliary Therapeutic Procedure...	23 (.13%)
Communication Disorders	22 (.12%)
Anemias Nonhemolytic And Marrow Dep...	21 (.12%)
Gastrointestinal Conditions	21 (.12%)
Microbiology And Serology	20 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Xylocaine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Xylocaine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.